Epigallocatechin gallate (EGCG)
Epigallocatechin gallate (EGCG) is the primary bioactive catechin in green tea and one of the most extensively researched polyphenols in cancer prevention, cardiometabolic health, and neuroprotection. It inhibits multiple oncogenic receptor tyrosine kinases including EGFR and HER2, suppresses mTORC1 and mTORC2 through Raptor displacement, activates the NRF2 antioxidant pathway, directly inhibits MMP9 matrix remodeling, and functions as a potent COMT inhibitor that can modulate dopamine availability depending on COMT genotype.
Key Takeaways
- •The most abundant polyphenol in green tea and one of the most potent natural inhibitors of receptor tyrosine kinases including EGFR (ErbB1) and HER2 (ErbB2), blocking their autophosphorylation and downstream RAS-MEK-ERK and PI3K-AKT-mTOR growth signaling cascades.
- •Inhibits both mTORC1 and mTORC2 through competitive binding at the ATP-binding site of mTOR and by disrupting the Raptor-mTOR interaction required for mTORC1 substrate recognition, producing autophagy induction and antiproliferative effects across multiple cancer models.
- •A potent NRF2 (NFE2L2) activator that induces the antioxidant response element gene set including catalase, glutathione peroxidase, SOD2, and heme oxygenase-1; this transcriptional antioxidant program provides durable protection beyond EGCG direct radical scavenging.
- •A natural COMT inhibitor that slows catecholamine O-methylation; individuals with the high-activity COMT Val158Met genotype may experience modest dopamine increases from EGCG, while low-COMT-activity individuals should use it cautiously as it can impair catecholamine clearance.
- •Directly binds to and inhibits the catalytic domain of MMP9 (matrix metalloproteinase-9), providing direct tissue-protective and anti-invasive activity relevant to both cancer prevention and inflammatory conditions that drive extracellular matrix degradation.
- •Downregulates FTO expression and promotes adipocyte browning, supporting metabolic flexibility and thermogenesis through a mechanism involving enhanced m6A methylation of adipogenic mRNA targets.
- •Bioavailability is low (approximately 1 to 2 percent) from green tea beverage but significantly improved with green tea extract capsules taken on an empty stomach; the methylated form EGC is absorbed more efficiently than EGCG.
Basic Information
- Name
- Epigallocatechin gallate (EGCG)
- Also Known As
- EGCGepigallocatechin-3-gallategreen tea catechingreen tea extractGTE(-)-epigallocatechin-3-O-gallate
- Category
- Flavan-3-ol catechin polyphenol / Receptor tyrosine kinase inhibitor
- Bioavailability
- Low to moderate. EGCG from green tea beverage has approximately 1 to 2 percent absolute oral bioavailability due to poor intestinal absorption, first-pass metabolism, and colonic degradation by gut bacteria. Green tea extract capsules taken on an empty stomach provide 3 to 4-fold higher plasma EGCG compared to tea beverage. Peak plasma levels reached 1.5 to 2 hours post-dose. EGCG is extensively glucuronidated and sulfated in the gut wall and liver. Phospholipid complexes (green tea phytosome) improve bioavailability significantly. Taking with food reduces peak absorption by 25 to 60 percent.
- Half-Life
- Plasma half-life of free EGCG is approximately 2 to 3.5 hours; conjugated metabolites persist longer. The relatively short half-life supports twice-daily dosing for sustained plasma coverage. Some metabolites including EGC and EC may retain partial biological activity.
Primary Mechanisms
EGFR, HER2, and other ErbB family receptor tyrosine kinase inhibition
mTORC1 and mTORC2 suppression through Raptor displacement and ATP-site competition
NRF2/NFE2L2 pathway activation and antioxidant gene induction
MMP9 direct catalytic domain binding and inhibition
COMT enzyme inhibition (natural catechol competitor)
FTO expression downregulation and adipocyte browning promotion
BRAF-MEK-ERK pathway modulation
MDM2-p53 interaction disruption to restore p53 tumor suppressor function
Quick Safety Summary
Clinical trials have used 100 mg to 800 mg per day of EGCG (standardized green tea extract). Most human bioavailability and pharmacological studies use 200 to 400 mg per day. High doses above 800 mg per day have been associated with hepatotoxicity in rare cases, particularly when taken on an empty stomach at doses exceeding 1,000 mg EGCG per day. The European Food Safety Authority concluded that habitual intake of green tea infusions is safe, but concentrated supplement doses above 800 mg EGCG per day require liver enzyme monitoring. Maximum safe supplemental dose is considered to be 400 to 600 mg per day in healthy adults.
Hepatic impairment: concentrated EGCG supplements at high doses have caused hepatotoxicity in susceptible individuals; individuals with pre-existing liver disease should avoid concentrated green tea extract supplements, Iron deficiency anemia: EGCG chelates non-heme iron in the GI tract with high affinity; take supplements away from iron-containing foods and supplements (at least 2 hours apart) to avoid reducing dietary iron absorption, Individuals with low COMT activity (Val/Met or Met/Met COMT genotype) may experience excessive catecholamine levels with high-dose EGCG; use lower doses (100 to 200 mg per day)
Overview
Epigallocatechin gallate (EGCG) is the most abundant and pharmacologically potent of the four major green tea catechins, accounting for 50 to 80 percent of the total catechin content in green tea (Camellia sinensis) leaves. Its biological importance extends far beyond simple antioxidant activity: EGCG directly inhibits multiple receptor tyrosine kinases, disrupts the mTOR kinase complex at two distinct levels, activates the NRF2 antioxidant transcription program, inhibits MMP9 through direct active-site binding, and modulates the epigenetic landscape through DNMT1 inhibition and histone modification. This multi-target pharmacology has made EGCG one of the most studied natural compounds in cancer chemoprevention research, with hundreds of preclinical studies and a growing body of human clinical and epidemiological evidence supporting benefits across cancer risk reduction, cardiovascular protection, metabolic health, and neuroprotection.
The mechanism of receptor tyrosine kinase inhibition by EGCG is direct and well-characterized. EGCG binds to the ATP-binding pocket of the EGFR kinase domain in a competitive manner, reducing the Km for ATP and impairing autophosphorylation at the critical Y1068, Y1086, Y1148, and Y1173 sites. This blocks EGFR recruitment of SH2-domain adaptor proteins (GRB2, SHC) and the downstream activation of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR signaling cascades. A similar inhibitory interaction has been characterized for HER2 (ErbB2), MET, and IGF1R. In cell culture and xenograft models, these kinase inhibitory effects produce antiproliferative, pro-apoptotic, and anti-invasive outcomes. The concentrations required for significant kinase inhibition in vitro (typically 10 to 50 micromolar) are difficult to achieve systemically with oral dosing, but the high concentrations in the GI tract lumen after oral administration may be sufficient for luminal effects relevant to colorectal cancer prevention.
EGCG activates the NRF2 antioxidant pathway through a mechanism involving electrophilic modification of specific cysteine residues on KEAP1, the E3 ubiquitin ligase adaptor that normally targets NRF2 for proteasomal degradation. EGCG and its quinone metabolites can directly oxidize KEAP1 cysteines at the Cys151, Cys273, and Cys288 sensors, destabilizing the KEAP1-NRF2 complex and allowing newly synthesized NRF2 to accumulate and translocate to the nucleus. NRF2 nuclear translocation activates the antioxidant response element (ARE) gene battery, inducing catalase, superoxide dismutase 2, glutathione peroxidase 1, glutathione-S-transferases, heme oxygenase-1, and NAD(P)H quinone oxidoreductase 1. This transcriptional induction provides a durable, sustained antioxidant protection that persists well beyond the short plasma half-life of EGCG itself.
The interaction between EGCG and COMT (catechol-O-methyltransferase) is clinically significant and genotype-dependent. EGCG is a natural catechol that competitively inhibits COMT by occupying the catechol substrate binding site. This slows the O-methylation of dopamine, norepinephrine, and catechol estrogens. In individuals with the high-activity COMT Val158Val genotype (commonly called Warriors), this inhibition modestly raises dopamine levels and may enhance working memory and reduce stress. In individuals with the low-activity COMT Val158Met or Met158Met genotype (Worriers), COMT activity is already reduced, and EGCG-mediated inhibition can lead to excess catecholamine accumulation, worsening anxiety and impairing prefrontal cortex function. This pharmacogenomic interaction means that the behavioral effects of green tea and EGCG supplementation are substantially influenced by COMT genotype.
Gene Interactions
Key Gene Targets
CAT
Induces catalase (CAT) gene expression through NRF2 pathway activation; the ARE elements in the CAT promoter are activated downstream of EGCG-driven KEAP1 oxidation and NRF2 nuclear translocation, increasing hydrogen peroxide detoxification capacity.
CCND1
Reduces CCND1 (Cyclin D1) transcription by interfering with the upstream growth signaling cascades (EGFR, HER2, STAT3) that drive CCND1 expression, and by activating p21/WAF1 which suppresses CDK4/6 activity; this cell cycle arrest activity is relevant to cancer prevention.
COMT
A potent natural COMT inhibitor that competitively occupies the catechol substrate binding site; EGCG slows dopamine, norepinephrine, and catechol estrogen O-methylation, making its dopamine-modulating effect strongly genotype-dependent: beneficial for high-COMT (Val/Val) individuals, potentially problematic for low-COMT (Met/Met) individuals.
EGFR
Directly inhibits EGFR tyrosine kinase by binding to the ATP-binding pocket of the kinase domain, reducing EGFR autophosphorylation and blocking recruitment of downstream SH2-domain effectors; this anti-EGFR activity is the best-characterized receptor kinase inhibitory mechanism of EGCG.
ERBB2
Inhibits HER2 (ErbB2) tyrosine kinase activity through a mechanism analogous to EGFR inhibition, reducing HER2 autophosphorylation and the formation of HER2-containing heterodimers that amplify growth signaling; relevant to HER2-overexpressing breast and gastric cancer prevention models.
MMP9
Directly binds to and inhibits the catalytic zinc-containing active site of MMP9 (matrix metalloproteinase-9), providing direct tissue-protective and anti-invasive activity; this is one of the few natural compounds with a characterized direct enzyme inhibitory interaction with MMP9.
MTOR
Inhibits both mTORC1 and mTORC2 through competitive binding at the ATP-binding site of the mTOR kinase domain and by disrupting the Raptor-mTOR interaction required for mTORC1 substrate recruitment; AMPK is co-activated, reinforcing mTOR suppression through the AMPK-TSC2-mTOR axis.
NFE2L2
A potent activator of the NRF2 (NFE2L2) pathway through KEAP1 modification by EGCG quinone metabolites; the resulting NRF2 nuclear accumulation and ARE gene induction drives the transcription of a comprehensive antioxidant enzyme battery including catalase, SOD2, GPX, and NQO1.
RB1
Inhibits CDK4 and CDK6 activity by reducing Cyclin D1 levels and activating p21/WAF1, keeping the RB1 retinoblastoma protein in its hypophosphorylated, transcriptionally repressive state; this CDK inhibition-mediated RB1 activation contributes to EGCG cell cycle arrest and tumor suppressor reactivation.
RPTOR
Disrupts the interaction between Raptor (RPTOR) and mTOR, impairing the substrate recruitment function of the mTORC1 complex; by interfering with Raptor binding, EGCG reduces mTORC1 activity independently of AKT and TSC2, contributing to its anti-proliferative mechanism.
STAT3
Inhibits STAT3 phosphorylation at Tyr705 by blocking JAK2 activity and possibly through direct interaction with the STAT3 SH2 domain; reduced STAT3 activation leads to decreased expression of anti-apoptotic genes (BCL-2, MCL-1, survivin) and pro-inflammatory cytokines, contributing to re-balancing the inflammatory tone of aging tissues.
TP53
Inhibits the MDM2-p53 interaction by occupying a binding interface on MDM2 that overlaps with the p53-binding site; this MDM2 displacement stabilizes p53 protein and allows p53 transcriptional activity to be restored in cancer cells where MDM2 overexpression has suppressed the p53 tumor suppressor program.
Safety & Dosing
Contraindications
Hepatic impairment: concentrated EGCG supplements at high doses have caused hepatotoxicity in susceptible individuals; individuals with pre-existing liver disease should avoid concentrated green tea extract supplements
Iron deficiency anemia: EGCG chelates non-heme iron in the GI tract with high affinity; take supplements away from iron-containing foods and supplements (at least 2 hours apart) to avoid reducing dietary iron absorption
Individuals with low COMT activity (Val/Met or Met/Met COMT genotype) may experience excessive catecholamine levels with high-dose EGCG; use lower doses (100 to 200 mg per day)
Drug Interactions
Iron supplements and iron-rich foods: EGCG forms stable chelates with non-heme iron, significantly reducing iron absorption; separate by at least 2 hours
Stimulant medications and caffeine: green tea extract supplements containing caffeine have additive CNS stimulant and cardiovascular effects; choose decaffeinated EGCG for cardiovascular conditions
Bortezomib (proteasome inhibitor): EGCG has been shown in vitro to inhibit bortezomib activity through direct binding; avoid concurrent use during bortezomib chemotherapy
Nadolol (beta-blocker): EGCG inhibits OATP1A2 transporters, reducing nadolol plasma levels by approximately 85 percent; avoid combining with nadolol
Anticoagulants: EGCG has mild antiplatelet and anticoagulant activity; monitor INR if combining with warfarin
Common Side Effects
Nausea and GI discomfort, particularly when high-dose concentrated extracts are taken on an empty stomach; resolved by taking with food despite the absorption trade-off
Insomnia and nervousness if the extract contains caffeine and taken in the afternoon or evening
Iron deficiency (with high-dose long-term use without attention to food timing) in individuals with borderline iron status
Rare hepatotoxicity with concentrated extracts above 800 mg EGCG per day; liver enzyme monitoring recommended at high doses
Studied Doses
Clinical trials have used 100 mg to 800 mg per day of EGCG (standardized green tea extract). Most human bioavailability and pharmacological studies use 200 to 400 mg per day. High doses above 800 mg per day have been associated with hepatotoxicity in rare cases, particularly when taken on an empty stomach at doses exceeding 1,000 mg EGCG per day. The European Food Safety Authority concluded that habitual intake of green tea infusions is safe, but concentrated supplement doses above 800 mg EGCG per day require liver enzyme monitoring. Maximum safe supplemental dose is considered to be 400 to 600 mg per day in healthy adults.
Mechanism of Action
EGCG exerts its effects through direct molecular interactions and through downstream signaling consequences. At the receptor level, EGCG competes with ATP for binding to the kinase domains of EGFR (IC50 approximately 10 to 30 micromolar), HER2, MET, and IGF1R, reducing their autophosphorylation and blocking recruitment of downstream SH2-domain signal transducers. This impairs the activation of both the RAS-RAF-MEK-ERK mitogenic cascade and the PI3K-AKT-mTOR survival and growth cascade. The mTOR suppression is reinforced by a second mechanism: EGCG disrupts the interaction between Raptor and mTOR, impairing the substrate recruitment function of mTORC1 without requiring AKT inhibition.
At the transcriptional level, EGCG activates NRF2 through modification of KEAP1 cysteine sensor residues, allowing NRF2 to accumulate in the nucleus and drive transcription of the antioxidant response element gene battery. This provides durable antioxidant enzyme induction that outlasts the EGCG pharmacokinetic window. EGCG also inhibits DNMT1 activity, contributing to demethylation of tumor suppressor gene promoters in cancer prevention contexts, and inhibits histone deacetylase activity in some models, creating an epigenetic profile supportive of anti-aging and anti-cancer gene expression.
Clinical Evidence
Human clinical evidence for EGCG is most established for cardiovascular and metabolic applications. Meta-analyses of randomized trials consistently show that green tea extract supplementation reduces total cholesterol, LDL cholesterol, and triglycerides, and modestly improves fasting glucose and insulin sensitivity. A large meta-analysis of 31 trials confirmed significant LDL and total cholesterol reductions in overweight adults. Blood pressure reduction has been documented in multiple meta-analyses, with effects of approximately 2 to 3 mmHg systolic in hypertensive individuals. Anti-inflammatory effects have been confirmed with reductions in CRP, IL-6, and TNF-alpha in clinical trials. For cognitive applications, a 2014 RCT in healthy adults demonstrated that 300 mg of green tea extract per day improved working memory and increased connectivity between parietal and prefrontal cortex by functional MRI. The prostate cancer prevention trial showing 90 percent relative risk reduction with 600 mg of green tea catechins per day in men with HGPIN remains the most striking cancer prevention finding in any polyphenol trial in humans. Overall, EGCG has one of the strongest evidence bases among botanical antioxidants, with clinical effects confirmed across multiple independent research groups.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Early mechanistic demonstration that EGCG inhibits epidermal growth factor receptor tyrosine kinase activity and downstream EGFR autophosphorylation, establishing the receptor kinase inhibitory mechanism as a primary anticancer activity of the green tea catechin.
Mechanistic study demonstrating that EGCG inhibits both mTORC1 and mTORC2 signaling complexes in breast cancer cells, including the Raptor displacement mechanism, establishing the dual mTOR complex inhibition that distinguishes EGCG from single-complex mTOR inhibitors.
Demonstrates that EGCG reduces insulin resistance and promotes adipose browning in obesity models through downregulation of FTO m6A demethylase expression, providing the mechanism for the metabolic and thermogenic effects of green tea catechins independent of direct receptor kinase inhibition.
Meta-analysis of 31 randomized controlled trials confirming that green tea supplementation significantly reduced total cholesterol and LDL cholesterol in overweight and obese adults, with effects on total cholesterol of approximately 4 mg/dL and LDL of approximately 2 mg/dL, providing human clinical evidence for the lipid-modulating activity.
Documents the direct inhibitory interaction between EGCG and the catalytic domain of MMP9, providing structural and biochemical evidence for the direct enzyme binding mechanism and demonstrating protective effects against MMP9-driven tissue degradation in muscle models.